ArticleCancer medicine2026
Early Mycophenolate Mofetil Combination Therapy as an Effective Approach for Immune-Related Hepatitis Induced by Immune Checkpoint Inhibitors in Patients With Solid Tumor.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune-related hepatitis (ir-hepatitis) is an immune-related adverse event that can be resistant to systemic steroid therapy. Mycophenolate mofetil (MMF) is recommended for steroid-refractory cases; however, evidence supporting its efficacy remains unclear. We aimed to evaluate the efficacy of MMF in patients with solid tumors, the optimal timing for administration, and its effect on cumulative steroid dosage.
methodsA retrospective cohort analysis was conducted between January 2015 and August 2023. We obtained data from eligible consecutive patients who developed ir-hepatitis with grade ≥ 2 alanine aminotransferase (ALT) elevation requiring systemic steroids. Participants were divided into three groups: MMF-early combination, MMF-late combination, and systemic steroid-only. ALT improvement rate was used to assess the efficacy of MMF based on the Common Terminology Criteria for Adverse Events version 5.0.
resultsAmong 4405 patients treated with immune checkpoint inhibitors, 151 (3.4%) developed ir-hepatitis requiring systemic steroids, of whom 123 had grade ≥ 2 ALT elevation. The median patient age was 62 years (interquartile range: 54-72), and 42 patients (34%) received MMF. Forty-one patients were evaluable for MMF timing. The ALT improvement rate on day 7 was significantly higher in the MMF-early combination group (n = 10) than in the MMF-late combination group (n = 31) (78.5% vs. 41.6%, p < 0.01). Among 40 patients evaluable for steroid dosage, cumulative systemic steroid dosage was significantly lower in the MMF-early combination group (n = 8) than in the MMF-late combination group (n = 32) (2121 mg vs. 3745 mg, p = 0.03). These effects were comparable even for the MMF-early combination and systemic steroid-only groups.
conclusionsDespite the small sample size, early combination therapy with MMF and systemic steroids rapidly improved ir-hepatitis, consequently reducing the cumulative systemic steroid dosage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.